Skip to main content

avacincaptad pegol

Generic: ACP·Brand: IZERVAY·Code: OPH2003, ISEE2008

avacincaptad pegol: 2 clinical trials tracked.

avacincaptad pegol evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about avacincaptad pegol, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Geographic Atrophy
Clinical Trial Registry Records (2)

A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT04435366Registry updated 2025-10-21·Phase 3·ISEE
Completed

Primary endpoint: The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12

InterventionalRandomizeddouble448 enrolledStarted 2020-06Completion 2023-0850 sites · United StatesIVERIC bio, Inc.

A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658Registry updated 2025-06-10·Phase 2/Phase 3·ISEE
Completed

Primary endpoint: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence

InterventionalRandomizeddouble286 enrolledStarted 2015-12Completion 2020-0450 sites · United StatesIVERIC bio, Inc.